Risk factors and prevention of thrombosis in patients with COVID-19

April 28, 2021
932
Resume

The article presents a review of the literature on the study of risk factors and prevention of thrombosis in patients with COVID-19. COVID-19 coagulopathy is characterized by increased levels of fibrinogen and D-dimer, moderate thrombocytopenia and slight increase of prothrombin time. The main risk factors that increase the probability of thromboembolic events are old age (>60 years), male gender, hypertension, diabetes and obesity. For standard stratification of thrombosis risk in modern conditions, it is necessary to use a modified IMPROVE scale, which is the most optimal for use in patients with COVID-19 and takes into account all indicators for calculating the risk of thromboembolism in such patients. The use of low molecular weight heparins is indicated to prevent thrombosis in patients with COVID-19. Taking anticoagulants after discharge from the hospital may be considered if there is a high risk of thrombosis and a low risk of bleeding. The question of taking antiplatelet agents to reduce the risk of thrombosis remains open and needs further study.

References:

  • 1. Johns Hopkins University and Medicine (2021) COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) (https://coronavirus.jhu.edu/map.html).
  • 2. Di Minno A., Ambrosino P., Calcaterra I., Di Minno M.N.D. (2020) COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Semin. Thromb. Hemost., 46(7): 763–771. doi: 10.1055/s-0040-1715456
  • 3. Mei H., Luo L., Hu Y. (2020) Thrombocytopenia and thrombosis in hospitalized patients with COVID-19. J. Hematol. Oncol., 13(1): 13–15. doi: 10.1186/s13045-020-01003-z
  • 4. Helms J., Tacquard Ch., Severac F. et al. (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med., 46(6): 1089–1098. doi: 10.1007/s00134-020-06062-x
  • 5. Ackermann M., Verleden S.E., Kuehnel M. et al. (2020) Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med., 383(2): 120–128. doi: 10.1056/NEJMoa2015432
  • 6. Bilaloglu S., Aphinyanaphongs Y., Jones S. et al. (2020) Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA, 324(8): 799–801. doi: 10.1001/jama.2020.13372
  • 7. Cantador E., Núñez A., Sobrino P. et al. (2020) Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients. J. Thromb. Thrombolysis, 50(3): 543–547. doi: 10.1007/s11239-020-02176-7.
  • 8. Lodigiani C., Iapichino G., Carenzo L. et al. (2020) Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb. Res., 191: 9–14. doi: 10.1016/j.thromres.2020.04.024
  • 9. Fajgenbaum D.C., June C.H. (2020) Cytokine Storm. New Eng. J. Med., 383(23): 2255–2273. doi: 10.1056/nejmra2026131
  • 10. Al-Ani F., Chehade S., Lazo-Langner A. (2020) Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb. Res., 192: 152–160. doi: 10.1016/j.thromres.2020.05.039
  • 11. Helms J., Tacquard C., Severac F. et al. (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intens. Care Med., 46(6): 1089–1098. doi: 10.1007/s00134-020-06062-x
  • 12. Mestres G., Puigmacià R., Blanco C. et al. (2020) Risk of peripheral arterial thrombosis in COVID-19. J. Vasc. Surg., 72(2): 756–757. doi: 10.1016/j.jvs.2020.04.477
  • 13. Miesbach W., Makris M. (2020) COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin. Appl. Thromb. Hemost., 26. doi: 10.1177/1076029620938149
  • 14. Holst A.G., Jensen G., Prescott E. (2010) Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation, 121(17): 1896–1903. doi: 10.1161/CIRCULATIONAHA.109.921460
  • 15. Benito N., Filella D., Mateo J. et al. (2020) Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19. Front. Med. doi: 10.3389/fmed.2020.00557
  • 16. Marcos S.Z., Antelo M.L., Galbete A. et al. (2020) Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group. Med. Clin. (Engl. Ed.), 155(8): 340–343. doi: 10.1016/j.medcle.2020.06.013
  • 17. Shibabaw T. (2020) Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy. J. Inflamm. Res., 13: 673–680. doi: 10.2147/JIR.S278335
  • 18. Nasonov E., Samsonov M. (2020) The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed. Pharmacother., 131: 110698. doi: 10.1016/j.biopha.2020.110698
  • 19. Dong Sh., Pei B., Xie W. et al. (2020) Anticardiolipin antibody and anti-β2 glycoprotein I antibody are potential risk markers of ischaemic stroke in Chinese adults. Rheumatology (Oxford), 59(8): 1834–1841. doi: 10.1093/rheumatology/kez551
  • 20. Harzallah I., Debliquis A., Drénou B. (2020) Lupus anticoagulant is frequent in patients with Covid-19. J. Thromb. Haemost., 18(8): 2064–2065. doi: 10.1111/jth.14867
  • 21. Guan W.J., Ni Z.Y., Hu Y. (2020) Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 382: 1708–1720.
  • 22. Tang N., Li D., Wang X., Sun Z. (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost., 18(4): 844–847. doi: 10.1111/jth.14768
  • 23. Spyropoulos A.C., Levy J.H., Ageno W. et al. (2020) Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemost., 18(8): 1859–1865. doi: 10.1111/jth.14929
  • 24. White D., MacDonald S., Bull T. et al. (2020) Heparin resistance in COVID-19 patients in the intensive care unit. J. Thromb. Thrombolysis, 50(2): 287–291. doi: 10.1007/s11239-020-02145-0
  • 25. Cuker A., Peyvandi F. (2021) COVID-19: Hypercoagulability (https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-hypercoagulability).
  • 26. Yavelov I.S., Drapkina O.M. (2020) COVID-19: Hemostatic parameters and specifics of antithrombotic treatment. Cardiovasc. Ther. Prevent., 19(3): 2571. doi: 10.15829/1728-8800-2020-2571. (In Rus.).
  • 27. https://clinicaltrials.gov/ct2/show/NCT01583218
  • 28. Revel M.-P., Parkar A.P., Prosch H. et al. (2020) COVID-19 patients and the radiology department – advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). Eur. Radiol. (https://doi.org/10.1007/s00330-020-06865-y).
  • 29. ESC (2020) ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic (http://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance).
  • 30. Piazza G., Morrow D.A. (2020) Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19 (https://jamanetwork.com/journals/jama/fullarticle/2773516).
  • 31. Lemos A.C.B., Santo D.A.D.E., Salvetti M.C. et al. (2020) Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb. Res., 196: 359–366.
  • 32. Tang N., Bai H., Chen X. et al. (2020) Anticoagulant treatment is associated with decreased mortality (https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14817).
  • 33. Ranucci M., Ballotta A., Di Dedda U. et al. (2020) The procoagulant pattern of patients with COVID‐19 acute respiratory distress syn-drome (https://onlinelibrary.wiley.com/doi/10.1111/jth.14854).
  • 34. NIH (2020) Coronavirus Disease 2019 (COVID-19) Treatment Guidelines (https://www.covid19treatmentguidelines.nih.gov/).
  • 35. Roberts L.N., Whyte M.B., Georgiou L. et al. (2020) Postdischarge venous thromboembolism following hospital admission with COVID-19. Thromb. Hemost., 136(11): 1347–1350.
  • 36. Patell R., Bogue Th., Koshy A. et al. (2020) Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood, 136(11): 1342–1346. doi: 10.1182/blood.2020007938
  • 37. https://www.evms.edu/media/evms_public/departments/internal_medicine/Marik-Covid-Protocol-Summary.pdf
  • 38. Chow J.H., Khanna A.K., Kethireddy Sh. et al. (2021) Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019. Anesth. Analg., 132(4): 930–941. doi: 10.1213/ANE.0000000000005292
  • 39. DiNicolantonioa J.J., Barroso-Arandab J. (2020) Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. Med. Hypotheses., 143: 110051. doi: 10.1016/j.mehy.2020.110051